Full Arvinas, Pfizer data confirm potential, limits of ‘Protac’ drug in breast cancer
While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free survival was modest.
While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free survival was modest.
